Studies that have compared HbA 1c levels by race have consistently demonstrated higher HbA 1c levels in African Americans than in whites. These racial differences in HbA 1c have not been explained by measured differences in glycemia, sociodemographic factors, clinical factors, access to care, or quality of care. Recently, a number of nonglycemic factors and several genetic polymorphisms that operate through nonglycemic mechanisms have been associated with HbA 1c . Their distributions across racial groups and their impact on hemoglobin glycation need to be systematically explored. Thus, on the basis of evidence for racial differences in HbA 1c , current clinical guidelines from the American Diabetes Association state: "It is important to take. . .race/ethnicity. . .into consideration when using the A1C to diagnose diabetes." However, it is not clear from the guidelines how this recommendation might be actualized. So, the critical question is not whether racial differences in HbA 1c exist between African Americans and whites; the important question is whether the observed differences in HbA 1c level are clinically meaningful. Therefore, given the current controversy, we provide a PointCounterpoint debate on this issue. In the point narrative below, Dr. Herman provides his argument that the failure to acknowledge that HbA 1c might be a biased measure of average glycemia and an unwillingness to rigorously investigate this hypothesis will slow scientific progress and has the potential to do great harm. In the counterpoint narrative that follows Dr. Herman's contribution, Dr. Selvin argues that there is no compelling evidence for racial differences in the validity of HbA 1c as a measure of hyperglycemia and that race is a poor surrogate for differences in underlying causes of disease risk. (1) . The mean difference ranged from 0.2 to 2.0%, and the mean between-group difference was ;0.65% (1) .
Until the mid-2000s, the observed differences in HbA 1c by race were universally attributed to health disparities, that is, preventable differences in health indicators in different population groups. More recently, differences in HbA 1c were demonstrated in African American and white adults who were selected to have the same fasting and post-glucose load glucose levels. In the Diabetes Prevention Program (DPP), eligibility was based on both impaired fasting glucose (glucose levels of 95-125 mg/dL) and impaired glucose tolerance (2-h post-glucose load glucose levels of 140-199 mg/dL). Despite having comparable fasting and postglucose load glucose levels, African Americans had significantly higher HbA 1c levels than whites in the DPP (6.2 6 0.6% vs. 5.8 6 0.4%, P , 0.0001) both before and after adjusting for age, sex, BMI, blood pressure, fasting glucose, glucose area under the curve, corrected insulin response, and insulin sensitivity (2 (5) . It thus appears that racial differences in HbA 1c levels occur independently of glycemia across the spectrum of glucose tolerance and cannot be explained by access to care, quality of care, sociodemographic characteristics, or clinical characteristics.
Clearly, one can hypothesize that unmeasured differences in diet and physical activity between African Americans and whites might result in unmeasured differences in fasting and postprandial glucose levels. In reality, however, studies such as the National Health and Nutrition Examination Survey that have systematically assessed diet and physical activity in African American and white adults have not demonstrated differences in diet that might explain the observed findings (6). Other carefully performed studies have suggested that lifestyle factors such as dietary fat (7), alcohol (8) , and even cigarette smoking (9) may impact HbA 1c levels independent of glycemia. Additional studies are warranted to assess the independent contribution of these factors to racial differences in HbA 1c .
In addition to lifestyle factors, racial differences in red cell phenotypes may potentially account for racial differences in HbA 1c . Approximately a dozen single nucleotide polymorphisms (SNPs) have been associated with HbA 1c , and more than half of them appear to operate through "nonglycemic" mechanisms related to erythrocyte biology (10) . Although some evidence suggests that these polymorphisms may contribute little to the variation in HbA 1c observed on a population basis (11), more recent studies have cast doubt on this assertion. A recent report from the African Genome Variation Project identified a novel locus associated with HbA 1c levels in the HBA2 gene on chromosome 16 (P 5 6.9 3 10 -19
) (12) . This 3.8-kb deletion has been previously associated with the alpha thalassemia trait and is common among Africans in whom the minor allele frequency has been reported to be 25% as compared with less than 1% in Europeans (12) . Its potential impact on hemoglobin glycation warrants further investigation (12) . Similarly, three enzymes have been described that deglycate HbA 1c . Two of the three appear not to be present in humans, but the third, fructosamine 3-kinase, is present in the erythrocyte and has shown significant genome-wide association with HbA 1c in both Europeans and Asians (11, 13, 14) . This polymorphism warrants further investigation in African American populations. Although research to date has not definitively identified polymorphisms that might explain nonglycemic First, although it is clear that diabetic complications occur more frequently in African Americans than in whites, it is also clear that the major cause is not the difference in glycemia between African Americans and whites but the differences in income, education, access to care, quality of care, cardiovascular risk factor treatment, and risk factor control (15) . The greater unadjusted prevalence of diabetic complications in African Americans compared with whites is attenuated by adjustment for the more frequent occurrence of nonglycemic risk factors for diabetic complications in African Americans (15) .
Second, it has been argued that the association between HbA 1c and diabetic complications and comorbidities do not differ by race. Many of the studies purporting to demonstrate this lack of association between HbA 1c and complications across racial groups have assessed differences in the adjusted odds of diabetic complications and comorbidities between racial groups by calculating a P value for interaction (15, 16) . Failing to observe a significant P value for interaction, the authors have concluded that the association between HbA 1c and outcomes do not differ by race (15, 16) . A plausible alternative explanation for the failure to observe a significant interaction between African Americans and whites is insufficient statistical power, not the absence of an effect. Indeed, larger and more robust studies have demonstrated that the adjusted risk of diabetic complications, comorbidities, and death increase with HbA 1c and are greater in whites than in African Americans within HbA 1c categories $7% (17) (18) (19) . This suggests that at any given HbA 1c level $7.0%, glycemic exposure is greater in whites compared with African Americans or, conversely, that glycemic exposure is lower in African Americans than in whites at any given HbA 1c level.
The third problem with promoting a "one size fits all" HbA 1c target and ignoring potential racial differences in the association between glucose levels and HbA 1c is that such a policy might result in a greater incidence of hypoglycemia in African Americans. For over a decade, diabetes quality of care measures focused on the prevention of hyperglycemia and rewarded HbA 1c lowering to achieve target HbA 1c levels ,7%. This, combined with a desire to eliminate health disparities, resulted in a progressive diminution and indeed eradication of racial differences in HbA 1c in the U.S. between 1998 and 2010 (20) . Yet, achieving the same target HbA 1c levels in whites and in African Americans may predictably result in lower blood glucose levels in African Americans than in whites. Findings from the DURAbility of Basal versus Lispro mix 75/25 insulin Efficacy (DURABLE) trial illustrate this point (21) . In that trial, mean 7-point glucose profiles were assessed by selfmonitoring of blood glucose. In post hoc analyses, a mean 7-point glucose profile of 100 mg/dL corresponded to an HbA 1c of 7.2% in whites and 7.6% in African Americans (21) . Extrapolating from the same data set, a mean HbA 1c of 7.0% would correspond to a mean 7-point glucose profile of 89 mg/dL in whites and a mean 7-point glucose profile of 68 mg/dL in African Americans (21) .
Data from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, which was designed to achieve HbA 1c levels ,6% in the intensive treatment group and 7.0-7.9% in the standard treatment group, demonstrated an annual study-wide incidence of hypoglycemia requiring medical assistance of 3.14% in the intensive treatment group and 1.03% in the standard treatment group (22) . Strikingly, however, the hazard ratio for hypoglycemia requiring medical assistance was 1.43 (1.20-1.71, P , 0.0001) for African Americans compared with whites after adjusting for multiple risk factors including age, sex, duration of diabetes, BMI, and renal disease (22) . Other studies have demonstrated that rates of hospital emergency department visits for hypoglycemia are approximately twofold higher in African Americans than in whites (23). It thus appears that because at any given HbA 1c level, glucose levels are lower in African Americans compared with whites, the risk of severe hypoglycemia is increased in African Americans when efforts are made to treat African Americans and whites to the same target HbA 1c levels (24) .
In summary, consistent differences in mean HbA 1c levels have been observed by race. These differences cannot be entirely explained by measured differences in glycemia, differences in sociodemographic or clinical factors, or differences in access to care or quality of care. It is wrong to conclude that the observed differences in HbA 1c between African Americans and whites must not exist because we cannot explain them. Differences in the distribution of nonglycemic factors associated with hemoglobin glycation such as dietary fat, alcohol consumption, and cigarette smoking, should be explored across racial groups. In addition, genetic polymorphisms associated with HbA 1c that operate through "nonglycemic" mechanisms, their distributions across racial groups, and their impact on hemoglobin glycation need to be more systematically explored. Our current failure to identify and characterize these polymorphisms is not sufficient to dismiss the possibility that they exist. Finally, focusing on the greater rate of diabetic complications and comorbidities in African Americans compared with whites and single-mindedly focusing on glycemia as the cause neglects the contribution of nonglycemic risk factors and diverts attention from the need to address and control them. Focusing on a "one size fits all" target for HbA 1c while neglecting direct measures of glycemia such as the results of self-monitoring of blood glucose presents a real likelihood for harm. Although the evidence does not currently exist to state unequivocally that race alters HbA 1c independently of glycemia, the lack of direct evidence does not negate that possibility. As scientists, we must be willing to accept the possibility that there are alternative explanations for established dogma. The failure to acknowledge alternative hypotheses will slow scientific progress and has the potential to do great harm. 
